Prabhudas Lilladher's research report on Sharda Cropchem
We broadly retain our estimates for Sharda Cropchem (SHCR), given company’s decent performance amid challenging times in 3QFY23. SHCR reported strong revenue growth of 16% YoY, led by volume/price growth of 9%/7% YoY. Gross margins (GM) contracted by 340bps YoY to 30.5%, largely led by adverse forex impact (Euro/USD depreciated by 12% YoY during 3Q). While, lower GM coupled with lower other expenses restricted EBITDA margin contraction of 290bps YoY to 19.1% (incl. IU&AD write-off of Rs22mn in 3QFY23). Citing positive growth momentum across regions coupled with price hikes in the recent past, management remains confident of achieving 15-20% YoY revenue growth in FY23E.
Outlook
SHCR has taken several measures to mitigate adverse forex impact in the recent past and this should aid in supporting margins, going forward. That said, we largely maintain our estimates with unchanged TP of Rs660 based on 14XFY25 EPS. Maintain ‘BUY’.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.